Breaking News on Drug Discovery
All news articles > March 2006
| « Previous month | Next month » |
30-Mar-2006
Upstate and Cisbio launches kinase assay kits
Upstate and Cisbio have announced the launch of an assay for Serine/Threonine kinase screening that offers simplified kinase assay development, which allows for profiling and high-throughput screening (HTS) on a large range of Ser/Thr kinases, major targets in drug discovery.
Discovery of HIV protein opens up new drug production
Scientists have discovered the existence of a HIV accessory protein that disables host immunity via receptor-protein intermediary in a discovery that points to possible novel ways to fight AIDS, immune disorders and sepsis.
ExonHit deal yields promising breast cancer data
ExonHit and bioMirieux have announced that scientific data generated in the detection of breast cancer could well lead to the development of novel diagnostic tests that will enable the early detection of breast cancer from blood.
Has new technology hampered R&D productivity?
Despite the technological breakthroughs that have enhanced the R&D capabilities of pharmaceutical companies, drug research and development is facing a major problem as R&D productivity in the last decade is at a historical low despite recent innovations.
Agilent's software speeds up gene localisation
Agilent has upgraded its GeneSpring GX 7.3 gene expression informatics software, giving it new features designed to allow researchers to understand faster what their results really mean.
28-Mar-2006
Affymetrix announces new ChIP-On-Chip array range
Affymetrix introduces its new ChIP-On-Chip array product line that its designers hope will provide drug researchers with new whole-genome tools to assist scientists discover DNA-Protein interactions.
Covalent Group enters $2.1M hyponatremia contract
Outsourcing company, Covalent Group, has announced the signing of a $2.1M (€1.7M) contract to provide a range of services to support the research and development of new therapies to treat hyponatremia.
Enzyme inhibitors form basis of new SARS drugs
Researchers have discovered a series of enzyme inhibitors that appear to block the replication of the SARS virus - a finding that could help speed up the research and development of drugs used to treat the killer virus.
Tool to study brain development leads to new drugs
Scientists have made available a powerful new tool for studying brain development, which will help scientists discover the genetic origins of brain cancers, which could speed development of novel drugs to treat them.
Researchers aim to 'reverse' juvenile diabetes
New diabetes trials scheduled to start this spring have been heralded as groundbreaking as researchers aim to reverse juvenile diabetes of which numbers have been steadily on the rise in developed nations.
23-Mar-2006
EU approves alternatives to animal testing of drugs
The European Union has approved new alternatives to animal testing of drugs and chemicals, which will not only reduce the number of animals needed for testing, but will also increase the accuracy of the tests, thereby making the products concerned safer.
Vertex and CFFT enter CF drug development
Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, (CFFT) have announced they have entered into a collaboration to develop a novel, oral drug candidate for the treatment of cystic fibrosis (CF).
Plant-based technology forms new pharmaceuticals
An innovative technology derived from plants, which is designed for the production of new pharmaceuticals is to form the basis of a new company that is to focus on (bio)pharma firms involved in the discovery, development, production, and commercialisation of pharmaceuticals from plants.
BioTrove and Blue Sky introduce drug target screening solution
BioTrove and Blue Sky Biotech announce a collaborative effort to provide a unique service solution, utilising mass spectrometry-based high-throughput screening assays on previously unscreenable drug targets.
New study reveals pharma market grew 7 pc in 2005
According to a new report, the pharmaceutical market grew seven per cent, to $602 billion (€501 billion) in 2005. The report highlighted the emerging markets including China, Korea, Mexico, Russia and Turkey, which experienced double-digit growth, outpacing global performance and signalling important shifts in the marketplace.
21-Mar-2006
Shimadzu introduces latest ICP spectrometer
Shimadzu have introduced its latest emission spectrometer, which has been designed for use in pharmaceutical research and development whilst reducing reduced running-costs and high sensitivity and low contamination.
Tripos announces Abbott informatics agreement
Drug discovery outfit, Tripos, has announced details of a collaboration with Abbott, which is to concentrate on chemical design and synthesis in a deal that mirrors, those announced earlier in Q1 with Genzyme, GSK Research and Development and Schering-Plough Research Institute.
Earlier trials indicated similar drug has serious side effects
The drug trial catastrophe, which has endangered the lives of six male volunteers of which two are still in a coma, could've been avoided after a similar study conducted last year yielded similar side effects.
New brain disorder tools results in new drugs
Researchers have constructed a model of an axon, which they have used to reproduce a change in the axon's shape that is characteristic of neurodegenerative disorders. The model provides a new road to discovering new kinds of drugs for the treatment of these disorders.
NicOx and Merck sign antihypertensive agreement
NicOx and Merck have signed an agreement to collaborate on the development of new antihypertensive drugs. The agreement follows the successful completion of the companies' research collaboration, which has generated promising results.
16-Mar-2006
Emerging disease risks shape drug therapies
Researchers in the UK think that knowledge of 'movement routes' is the key to predicting patterns of spread of infectious diseases in humans, which would enable scientists to administer effective drug therapies that are able to halt the disease in the early stages.
Thermo speeds LC-MS/MS analysis up
Thermo has upped the stakes at the Pittcon exposition taking place this week in Orlando by unveiling QuickQuan, a fully automated, high-throughput software solution for the analysis of chemically diverse compounds, speeding up the pace of drug discovery to record levels through intelligent automation.
Bayer Healthcare selects Genedata's biomarker platform
Bayer Healthcare has selected Genedata's Bioinformatic platform for its target research and biomarker activities in which the deal will involve the mechanistic analysis of cardiovascular and cancer biomarker genes.
Parexel in hot water over drug trial scare
Parexel, one of the world's leading clinical research organisations is under investigation after six men in a UK drug trial being run by the company were admitted to intensive care on Tuesday.
ChemAxon and FMC agrees product acquisition
ChemAxon and FMC has announced a global all product license acquisition of ChemAxon's complete product line and the switching over to JChem cheminformatics platform.
14-Mar-2006
First-in-class drug aids myelodysplastic syndrome sufferers
A member of a new class of drugs may increase survival in patients with myelodysplastic syndrome (MDS), and could become the new standard of therapy for this group of pre-cancer disorders, said researchers.
Schering rejects Merck's KGaA takeover offer
German drug maker Schering has rejected Merck's unsolicited takeover offer of €14.6 billion ($17.4 billion), claiming the deal undervalued the company.
Novel menthol method points to new pain therapies
A new method has revealed that a discovery involving menthol could point towards new therapies to treat chronic inflammatory and neuropathic pain indications by targeting the temperature-activated ion channels.
Kreatech launches first miRNA isolation labelling kit
Kreatech has launched the first complete miRNA isolation and labelling kit, which combines the upstream isolation of small RNA and the reagents necessary to label these DNA samples for microarray analysis, offering a more complete miRNA analysis solution.
Bruker Daltonics introduces new molecular imager
Bruker Daltonics announces the release of its MALDI Molecular Imager, a system for in-vitro imaging of peptide and protein biomarker distributions in tissue sections and cell clusters. The imager addresses the need for high-sensitivity imaging of the spatial distribution of protein biomarkers in clinical research.
09-Mar-2006
Chemicon and SCS launch stem cell producing medium
Stem Cell Sciences have launched the first complete, defined medium that enables the large-scale, consistent production of mouse ES cells. The announcement closely follows the formation of an exclusive agreement completed last year between the two companies.
VGX and Dowpharma sign anti-cancer compound agreement
VGX and Dowpharma have signed an agreement to advance the development of a novel cancer compound currently in pre-clinical development that initial clinical studies will target individuals with Non-Hodgkin's Lymphoma.
Nucryst Pharmaceuticals granted new acne patent
Nucryst Pharmaceuticals has been granted a new patent that covers the company's proprietary nanocrystalline silver for use in the treatment of acne. This latest addition strengthens the company's patent portfolio, which now covers the top three dermatology diseases.
Research holds drug promise for Huntington's treatment
Researchers in the US think they have identified a compound that interferes with the pathogenic effects of Huntington's disease that could lead to the development of a new treatment for the disease as well as making an impact on similar disorders such as Parkinson's disease.
FEI and Sidec enter protein tomography deal
FEI and Sidec have entered into an agreement to commercialise a range of Protein Tomography solutions that could provide drug companies with services that could increase the chances of success in early stage drug development.
07-Mar-2006
Velocity11 introduces automated benchtop system
Velocity11 make available a benchtop microplate handling system that claims to provide the features and flexibility of much larger and more expensive automation platforms.
Protein receptor cools intensity of nerve cells
A newly discovered process that explains how the body's nervous system relays information, may depend on how "wet" the "kiss" is when one neuron fires a packet of neurotransmitter across a synapse to a receptive nerve cell.
EU drug approvals neglect rare disease treatments
New research has suggested only seven per cent of drug applications for treating people with rare diseases were approved in Europe between 2000 and 2004, despite the fact that there are currently more than 5,000 conditions needing medication.
Agilent Technologies introduces next-gen assay kits
Agilent introduces its next generation of assay kits for its 2100 Bioanalyser Lab-on-a-Chip platform that aims to replace labour-intensive SDS-PAGE and capillary gel electrophoresis (CGE) methods providing faster microfluidic analyses.
Studies suggest new targets for TB treatments
A new study has revealed the existence of new drug targets for tuberculosis (TB) treatments, which could essentially dictate the design of TB drugs of the future. The bacterium that causes TB currently infects one person in three worldwide.
02-Mar-2006
AGTC initiates gene therapy trial to treat emphysema
Applied Genetic Technologies Corporation (AGTC), announced today the initiation of a Phase 1 clinical study to test the safety of AGTC-0106, its investigational gene therapy product for patients with Alpha-1 Antitrypsin deficiency ("Alpha-1").
GE Healthcare introduces peptide separation system
GE Healthcare has announced the introduction of Ettan nanoLC, a fully bio-inert, robust, nanoscale peptide separation system that delivers highly reproducible performance and is ideal for 1D-liquid chromatography (LC) proteomics applications upstream from electrospray ionisation mass spectrometry (MS) or MALDI MS/MS applications.
Nastech acquires Galenea RNAi therapeutics program
Nastech Pharmaceutical Company, announced today the expansion of its RNAi therapeutics pipeline by initiating an RNAi therapeutics program targeting influenza and respiratory diseases.
New DNA recognition method determines drug design
Scientists have discovered a new way that drugs can attach themselves to DNA, providing a crucial step forward for those who are developing drugs to combat cancer and other diseases. The breakthrough heralds a new way of recognising DNA, which will hopefully lead to a new approach in designing drugs.
New treatments based on T-cell stimulation possible
Scientists have found that certain T-cell stimulation could help improve treatment of autoimmune disease and cancer, which could be significant for developing new drug treatments to help patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes.
| « Previous month | Next month » |
All Decision News Media Sites
Food & Beverage: Food & Beverage Development - Europe | Food & Beverage Development - North America | Food Marketing and Retailing | Food Processing & Packaging | Food Safety & Quality Control | Food and Beverage in Asia Pacific | Industrial Baking & Snacks | Beverage Technology & Markets | Confectionery & Biscuit Processing | Dairy Processing & Markets | Prepared Food and Meat Processing | Retail news Nutrition: Supplements & Nutrition - Europe | Supplements & Nutrition - North America Pharmaceutical: Pharmaceutical Technology | Contract Research, Manufacturing & Clinical Trials Cosmetics: Cosmetics Formulation & Packaging - North America | Cosmetics Formulation & Packaging - Europe
About us | Site map | All sites | Recommend this Site | Advertise | Contact the Editor | Terms & Conditions | Privacy Policy
©; 2000/2010 - Decision News Media SAS - All right reserved.
